Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer
10.3779/j.issn.1009-3419.2016.10.08
- VernacularTitle:厄洛替尼治疗34例肺鳞癌患者的疗效观察
- Author:
CHENG FANG
1
,
2
;
WANG JING
;
CHEN JIE
;
XING PUYUAN
;
LI JUNLING
Author Information
1. 100021北京，国家癌症中心/中国医学科学院北京协和医学院肿瘤医院
2. 100122北京，北京市朝阳区三环肿瘤医院
- Keywords:
Lung neoplasms;
Erlotinib;
EGFR-TKI
- From:
Chinese Journal of Lung Cancer
2016;19(10):679-681
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Epidermal growth factor receptor tyrosine kinase inhinitors (EGFR-TKIs) inhibit tumor growth by affecting signal transduction, and are well tolerated. hTe aims of this study was to observe the effect of erlotinib in patients with squamous cell lung cancer.Methods hTe 34 patients with squamous cell lung cancer treated with er-lotinib 150 mg orally once daily until disease progression or intolerable adverse reactions.Results hTe 7 patients were treated with erlotinib as ifrst-line treatment, 6 patients as maintenance therapy (1 case withdrawal of severe toxicity), 9 patients second-line treatment, 5 patients as third-line and 7 patients as further-line therapy. 11 patients died. hTe median progression-free sur-vival (PFS) was 3.5 months, ranging from 1 month to 55 months (the patient withdrawal of severe toxicity was not included). Conclusion Erlotinib was effective for patients with squamous cell lung cancer who can not tolerate chemotherapy or refused chemotherapy and with unknown EGFR status. Adverse reactions were tolerable.
